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What’s already known on this topic? 39 
Low levels of PAPP-A are associated with small for gestational age and pre-eclampsia. 40 
 41 
What does this study add? 42 
NT, CRL and PAPP-A are independent prognostic markers for adverse pregnancy outcome. 43 
Further work is required to assess the predictive ability of these factors in prediction 44 
models. 45 
 46 
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Abstract 47 
Objective 48 
Are first trimester serum pregnancy-associated plasma protein-A (PAPP-A), nuchal 49 
translucency (NT) and crown rump length (CRL) prognostic factors for adverse pregnancy 50 
outcomes? 51 
Method 52 
Retrospective cohort women, singleton pregnancies (UK 2011-2015). Unadjusted and 53 
multivariable logistic regression, outcomes: small for gestational age (SGA), pre-eclampsia 54 
(PE), pre-term birth (PTB), miscarriage, stillbirth, perinatal mortality and neonatal death 55 
(NND). 56 
Results 57 
12,592 pregnancies: 852 (6.8%) PTB, 352 (2.8%) PE, 1824 (14.5%) SGA, 73 (0.6%) 58 
miscarriages, 37(0.3%) stillbirths, 73 perinatal deaths (0.6%) and 38 (0.30%) NND. 59 
Multivariable analysis: lower odds of SGA [adjusted odds ratio (aOR) 0.88 (95% CI 60 
0.85,0.91)], PTB [0.92 (95%CI 0.88,0.97)], PE [0.91 (95% CI 0.85,0.97)] and stillbirth [ 0.71 61 
(95% CI 0.52,0.98)] as PAPP-A increases. Lower odds of SGA [aOR 0.79 (95% CI 0.70,0.89)] 62 
but higher odds of miscarriage [aOR 1.75 95% CI (1.12,2.72)] as NT increases, and lower 63 
odds of stillbirth as CRL increases [aOR 0.94 95% CI (0.89,0.99)]. Multivariable analysis of 64 
three factors together demonstrated strong associations: a) PAPP-A, NT, CRL and SGA, b) 65 
PAPP-A and PTB, c) PAPP-A, CRL and PE, d) NT and miscarriage. 66 
Conclusions  67 
PAPP-A, NT and CRL independent prognostic factor for adverse pregnancy outcomes, 68 
especially PAPP-A and SGA with lower PAPP-A associated with increased risk.  69 
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 70 
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Introduction 74 
Adverse pregnancy outcomes have a psychological impact for the family as well as 75 
an increased cost of healthcare. Methods of prediction would allow obstetricians to provide 76 
increased obstetric surveillance, focusing optimum management and possibly improving the 77 
outcome of the pregnancy. 78 
Pregnancy associated plasma protein A (PAPP-A) is a placental glycoprotein 79 
produced by syncytial trophoblast of the placenta, which cleaves insulin-like growth factor 80 
binding protein 4 (IGFBP4) and is a positive regulator of insulin-like growth factors (IGFs) 1, 81 
potentially influencing fetal growth and wellbeing. 82 
Studies have tested the hypothesis that low maternal serum levels of PAPP-A in the 83 
first trimester are prognostic factors for adverse pregnancy outcomes associated with poor 84 
placental function 2 3, 4 5 6. International Guidelines on “The Investigation and Management 85 
of the Small for Gestational Fetus” have recommended that pregnant women with a serum 86 
PAPP-A <0.4MoM (5th centile) in the first trimester receive increased ultrasound 87 
surveillance for fetal growth disorders7.  This recommendation was based on a previous 88 
systematic review by our group in 2008 assessing Down’s syndrome markers to predict pre-89 
eclampsia and SGA8. This review included only 16 studies, did not assess all outcomes and 90 
did not distinguish between prognosis and prediction. However, contradictory results have 91 
been observed in publications 
6, 9
 and few studies have investigated the association of first 92 
trimester fetal biometry [nuchal translucency (NT) and crown rump length (CRL)] with 93 
adverse outcomes and their relationship with PAPP-A 3, 10. Resolution of this is required, 94 
because genuine prognostic factors in this field have many potential uses. As outlined by the 95 
PROGRESS series 11-14, they may guide clinical decisions and monitoring strategies, inform 96 
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the design and analysis of new trials, and improve models for individualised risk prediction. 97 
Factors that add additional (independent) prognostic information are difficult to find, but 98 
are needed to improve the discrimination performance of a ‘prognostic model’13 that 99 
produces absolute risk predictions for women based on a set of individual characteristics11. 100 
Our objective was to undertake a large cohort study to determine whether serum PAPP-A, 101 
NT and CRL in the first trimester are independent prognostic factors for the risk of 102 
subsequent adverse pregnancy outcomes. 103 
 104 
Methods 105 
Data collection 106 
In a retrospective cohort study, data were collected from patients booked from 1st 107 
August 2011 (commencement of electronic maternity record) to 31st March 2015 at the 108 
Birmingham Women’s Foundation Trust (BWNFT), a secondary and tertiary care NHS 109 
hospital in West Midlands, UK. 110 
All pregnant women who accepted first trimester aneuploidy screening and 111 
delivered in BWNFT were included in the study. First trimester aneuploidy screening is 112 
offered to all pregnant women between 11+2 to 14+1 weeks of gestation (crown–rump 113 
length (CRL) measures from 45 mm to 84 mm) as part of the National Downs Syndrome 114 
Screening Programme
15, 16
. This involves measuring maternal serum levels of PAPP-A and 115 
free beta human chorionic gonadotrophin (fβHCG), along with the NT, and the pregnancy is 116 
dated on the basis of CRL. All first trimester scans and measurements performed at BWNFT 117 
are performed by accredited sonographers according to National NEQAS guidelines
17
. First 118 
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day of the last menstrual period was obtained from the referring letter from the community 119 
midwife or hospital. This date was confirmed with the mother at the ultrasound visit and 120 
additional information on the regularity and cycle duration was obtained.  121 
Analysis for PAPP-A was performed on the Auto-Delfia immunoassay platform 122 
(Perkin Elmer Ltd, Seer Green, UK). For the purpose of Down’s syndrome screening, PAPP-A 123 
values are converted to multiples of the median for gestation. In this study, to prevent any 124 
loss of data18 and to remove the need for considering an absolute threshold, PAPP-A values 125 
were considered as a continuous variable using the absolute value (mU/L). To aid the 126 
presentation and interpretation of results, PAPP-A values were rescaled by dividing the 127 
values by 1000, therefore the results relate to PAPP-A values in U/L. 128 
Multiple hospital-based, secure and confidential computerized databases were used 129 
to extract the information for the study and governance from the hospital-based IT and 130 
Caldecott Guardian were prospectively obtained. Maternal and pregnancy outcome data 131 
were collected from K2 database, Neonatal data were collected from Badgernet database, 132 
and biochemistry data were collected from a biochemistry database. The collected data 133 
consisted of maternal characteristics and demographics; maternal medical, antepartum, 134 
peripartum and pregnancy outcome data along with first trimester serum PAPP-A levels, NT 135 
and CRL. Multiple gestations, pregnancies with donor eggs, missing outcome and known 136 
fetal aneuploidy were excluded. Cases of aneuploidy were cross referenced with the West 137 
Midlands Regional Genetics Laboratory database. 138 
Definitions of maternal and obstetric characteristics 139 
Page 7 of 29
http://mc.manuscriptcentral.com/pd
Prenatal Diagnosis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
8 
 
Preterm birth (PTB) was defined as live delivery prior to 37 weeks, both spontaneous 140 
and iatrogenic. Pre-eclampsia (PE) was defined according to the International Society for the 141 
study of Hypertension in Pregnancy (ISSHP) definition as de-novo hypertension at or after 20 142 
weeks gestation (at least 2 readings of Blood Pressure >140 mmHg systolic or >90 mmHg 143 
diastolic) with proteinuria (spot urine protein/creatinine >30 mg/mmol [0.3 mg/mg] or >300 144 
mg/day or at least 1 g/L [‘2 + ’] on dipstick testing)19. Small for gestational age (SGA) was 145 
defined as birthweight below the 10th percentile of the customised growth chart20. 146 
Miscarriage was defined as fetal demise before 24 weeks of gestation. Stillbirth was defined 147 
as intrauterine death after 24 completed weeks of pregnancy. Perinatal death was defined 148 
as fetal or neonatal death between 24 weeks of gestation and 7 days after birth. Neonatal 149 
death was defined as death between birth and 28 days. 150 
Data Analysis 151 
Mother and fetus demographics and clinical features 152 
Distributions of demographic characteristics and known prognostic factors were 153 
summarised. The existing prognostic factors were those deemed to be important by the 154 
clinical team a prior and defined as: maternal age at test, gestational age at test, parity, 155 
body mass index (BMI), deprivation category (Index of Multiple Deprivation 2010 – IMD 16, 156 
calculated using National Perinatal Epidemiology Unit calculator), ethnicity, assisted 157 
conception (IVF), smoking status (non-smoker, stopped at booking or on-going smoker), pre-158 
pregnancy insulin-dependent diabetes mellitus, and gender of the baby. Mean and standard 159 
deviation (SD), or median and interquartile range (IQR), is reported for continuous variables, 160 
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according to whether the variables were normally distributed. The number and percentage 161 
are reported for categorical variables. 162 
Analysis of prognostic association with outcomes 163 
Univariable logistic regression analysis was used to estimate the unadjusted odds 164 
ratio (OR) for each potential prognostic factor (PAPP-A/NT/CRL) separately. The odds ratios 165 
indicate how much the odds of the outcome are increased for each 1-unit increase in the 166 
factor.  167 
Again for each of the three factors separately, multivariable logistic regression 168 
analyses were fitted to examine the odds ratio adjusted for the known (or likely) existing 169 
prognostic factors of maternal age (years), parity, BMI, smoking status, IVF, ethnicity, 170 
deprivation category and gestational diabetes. This provided the adjusted odds ratio for a 1-171 
unit increase in each factor, to reveal their independent prognostic value over and above 172 
other factors. 173 
Then, for each outcome, the three factors were analysed in combination in one 174 
multivariable logistic regression model, whilst adjusting for the other factors detailed above, 175 
to explore whether the prognostic value of each factor is the same after adjusting for the 176 
other two potential prognostic factors. The linearity assumption of all continuous variables 177 
was assumed for these multivariable models. 178 
Therefore, finally, the fully adjusted models with all three potential factors in 179 
combination were fitted again; however, additionally, the linearity assumption of the 180 
prognostic effects for the three factors of interest was assessed, and alternative functional 181 
forms were considered if the assumption was violated. Else, a linear relationship was 182 
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specified for all three prognostic factors of interest. The functional form was chosen using 183 
fractional polynomials, where all possible fractional polynomials up to the second degree 184 
were considered based on their statistical significance21. A linear relationship was specified 185 
for the other continuous covariates (maternal age and BMI). 186 
In all multivariable models described above, no model selection process was used to 187 
determine which factors were included in each model, since all variables were pre-specified. 188 
Handling of missing data 189 
The percentages of missing values for each covariate and outcome were calculated. 190 
Missing data was imputed with multiple imputation with chained equations with 35 191 
imputed datasets equal to the percentage of patients with missing data 22. For non-normally 192 
distributed variables, predictive mean matching was used to impute the missing data 23. The 193 
imputation model contained all complete outcomes and covariates that were included in 194 
the multivariable analyses. Rubin’s rules were used to combine the parameter estimates 195 
and standard errors into a single inference 24. A complete-case analysis was also conducted 196 
as a sensitivity analysis. 197 
Estimates of prognostic effects are reported as odds ratios (OR) with 95% confidence 198 
intervals (CI) and p-values. Analyses were performed using Stata version 14 25 and all 199 
regression models were fitted using maximum likelihood estimation. 200 
 201 
Results 202 
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Between August 2011 and March 2015, first-trimester combined screening was 203 
performed in 12,837 pregnant women. Ten pregnancies conceived with donor eggs were 204 
excluded. Three pregnancies with an unclear pregnancy outcome showing neonatal death 205 
post 28 days were excluded since this outcome would not be routinely recorded in the 206 
databases. After excluding 232 multiple pregnancies, the final study cohort was of 12,592 207 
singleton pregnancies. 208 
As depicted in Table 1, the mean maternal age and median BMI were 30.6 (SD 5.6) 209 
and 25.1 (IQR 22.4 to 28.8), respectively. The majority of the women were White British 210 
European (62.6%) followed by South Asian (19.9%). Mean gestational age at first trimester 211 
ultrasound was 88.2 days (SD 4.3). About 2% (n=250) of pregnancies were the result of 212 
assisted conception. Smoking status was known for all women and 12.4% were on-going 213 
smokers in the pregnancy, 84.3% non-smokers and 3.3% had given up at the time of first 214 
trimester booking appointment. Nearly half (43%, n=5495) patients lived in the most 215 
deprived areas (deprivation score ≥ 34.18) and 3.6% (n=455) patients lived in the least 216 
deprived areas (deprivation score ≤ 8.49). Gender distribution was almost equal in the 217 
fetuses (48.6% male and 51.1% female). 218 
BMI was missing in 4466 (35.5%) records, parity was missing in 567 (4.5%) and 219 
deprivation score was missing in 175 (1.4%) records. There were missing data for 152 (1.2%) 220 
fetal weight and four (0.03 %) neonatal outcomes. Multiple imputation was performed for 221 
missing BMI (height, weight), parity and deprivation score values. Although some variables 222 
were normally distributed, predictive mean matching was used for all variables because 223 
imputation with chained regression analysis imputed unrealistic values for weight and 224 
height. 225 
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Table 2 displays the number of events for each outcome for the cohort, and the 226 
prognostic association of PAPP-A, NT and CRL with these outcomes in the unadjusted 227 
analyses. Of 12,592 women, 852 had pre term birth (6.8%), 352 patients had pre-eclampsia 228 
(2.8%) and 1824 babies were SGA (14.5%). There were 73 pregnancies that ended in 229 
miscarriage (0.6%) and 37 stillbirths (0.3%). There were 38 neonatal deaths (0.31%) of which 230 
36 were early and thus giving a total of 73 perinatal deaths (0.6%). 231 
 232 
PAPP-A Results 233 
In the unadjusted analysis (Table 2), a one unit increase in the concentration of 234 
PAPP-A (U/L) was estimated to lower the odds of an SGA neonate by 13%, which was highly 235 
significant [OR 0.87 (95% CI 0.85, 0.90), p<0.0001]. Similar conclusions can be drawn for the 236 
association between PAPP-A and pre-term birth [OR 0.93 (95%CI 0.90, 0.97), p<0.0001] In 237 
addition, PAPP-A and pre-eclampsia demonstrated a similar relationship [OR 0.92 (95% CI 238 
0.86, 0.97), p=0.004]. The results for stillbirth were in the same direction and quantitatively 239 
similar, although the CI was slightly wider and the p-value was just above the 5% [OR 0.81 240 
(95% CI 0.66, 1.0), p=0.052]. There was no evidence of a strong association between PAPP-A 241 
and miscarriage, perinatal death or neonatal death. 242 
After adjusting for mother’s age, BMI, parity, ethnicity, deprivation score, smoking 243 
status, IVF status, and gestational diabetes in the multivariable analysis there was evidence 244 
of strong independent prognostic associations between: PAPP-A and SGA [OR 0.88 (95%CI 245 
0.85, 0.91), p<0.0001] (Table 3; full model parameter estimates for all adjusted models are 246 
shown in the Supporting Information Tables S1-S7 ); PAPP-A and PTB [OR 0.92 (95% CI 0.88, 247 
0.97), p=<0.0001]; and PAPP-A and PE [OR 0.91 (95% CI 0.85, 0.97), p=0.003]. There was also 248 
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evidence of a lower odds of a stillbirth as PAPP-A increases [OR 0.71 (95% CI 0.52, 0.98), 249 
p=0.038]. The association of PAPP-A with the outcomes of miscarriage (Table S4), perinatal 250 
death (Table S6) and neonatal death (Table S7) remained non-significant in the multivariable 251 
analyses. 252 
NT Results 253 
In the unadjusted analyses (Table 2), for higher values of NT there was a strong 254 
association with an increased odds of miscarriage [OR 1.94 (95% CI 1.54, 2.45), p<0.0001], 255 
and a significant decreased odds of SGA [OR 0.81 (95% CI 0.72, 0.91), p<0.0001]. There was 256 
also some evidence that higher values are associated with an increased risk of PTB [OR 1.15 257 
(95% CI 1.00, 1.32), p=0.053] though the CI overlapped one.  258 
After multivariable analysis, there was independent prognostic value of NT for SGA 259 
[OR 0.79 (95% CI 0.70, 0.89), p<0.0001] (Table 3 and Table S8), and for miscarriage [OR 1.75 260 
(95% CI 1.12, 2.72), p=0.013] (Table S11). There was no significant relationship between NT 261 
and PTB, PE, stillbirth, perinatal or neonatal death in the unadjusted or adjusted analyses 262 
(Table S9, S10, S12, S13, S14). 263 
CRL Results 264 
For CRL in the unadjusted analysis there was no significant association with any of 265 
the outcomes (Table 2). There was a borderline statistical significance for SGA which 266 
remained after adjustment [OR 0.99 (95% CI 0.99, 1.00, p=0.057)] (Table 3), but the 267 
magnitude of the OR was close to one. After adjustment for other known predictors and 268 
potential confounders, there was evidence of a strong association between CRL and 269 
stillbirth [OR 0.94 (95% CI 0.89, 0.99), p=0.027], thus between 1% and 11% lower odds of 270 
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stillbirth for a one unit increase in CRL. The adjusted analyses for PTB, PE, miscarriage, 271 
perinatal death and neonatal death demonstrated no significant association with CRL (Table 272 
S15 - S21). 273 
PAPP-A, NT and CRL in combination 274 
Assuming linear functions for all continuous variables, the three potential prognostic 275 
factors were then considered in combination with adjustment for confounders and known 276 
prognostic factors as discussed (Tables S22-28 in the Supporting Information). For SGA, this 277 
analysis demonstrated strong associations with PAPP-A [OR 0.87 (95% CI 0.84, 0.90), 278 
p<0.0001); NT [OR 0.80 (95% CI 0.70, 0.91); p=0.001] and CRL [OR 1.01 (95% CI 1.00, 1.03); 279 
p=0.004). 280 
For preterm birth (Table S23), only PAPP-A was significantly associated with reduced 281 
odds [OR 0.92 (95% CI 0.87, 0.96), p<0.0001], as seen when the factors were considered 282 
individually. For pre-eclampsia, PAPP-A was still significantly associated [OR 0.88 (95% CI 283 
0.82, 0.94); p=<0.0001] and now there was evidence of increased odds of pre-eclampsia as 284 
CRL increases [OR 1.02 (95% CI 1.01, 1.04); p=0.004] (Table S24). 285 
There remained a statistically significantly increased odds of miscarriage as NT 286 
increases [OR 1.67 (95% CI 1.01, 2.76), p=0.047], and no evidence of associations between 287 
miscarriage and PAPP-A or CRL (Table S25). There was not any strong evidence (e.g. based 288 
on statistical significance at the 5% level) of any associations between stillbirth and any of 289 
PAPP-A, NT or CRL, unlike the individual models (Table S26). There was no evidence of 290 
associations between any of the three factors of interest and perinatal or neonatal death 291 
(Table S27-28). 292 
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After checking the linearity assumption of the three prognostic factors, all the 293 
previously identified prognostic associations remained the same. However, the log 294 
transformation was statistically the best fitting functional form of PAPP-A for SGA, and 295 
1/  was statistically the best fitting functional form of PAPP-A for PTB. For PAPP-A for 296 
all other outcomes and for CRL and NT for all outcomes, the best fitting functional form was 297 
the linear function (See Tables S29-S31). 298 
All the findings remained the same in the complete case analysis. 299 
Discussion 300 
Main Findings 301 
This large cohort study provides strong evidence that lower values of PAPP-A are 302 
associated with an increased odds of SGA, stillbirth, PE and PTB. As NT increases there is 303 
evidence of a lower odds of SGA but higher odds of miscarriage. As CRL decreases there is 304 
evidence of higher odds of stillbirth. Neonatal and perinatal deaths were not associated 305 
with any of the prognostic factors measured in the first trimester. When considered in 306 
combination there is a statistically significant association of PAPP-A, NT and CRL with SGA; 307 
preterm birth with PAPP-A, pre-eclampsia with PAPP-A and CRL, and miscarriage with NT. In 308 
the combined model stillbirth is no longer associated with any of the factors. 309 
 310 
Strengths and Limitations:  311 
Our study has several strengths. This is a large cohort study looking at multiple 312 
pregnancy outcomes providing reproducible statistical results. The UK is a country where 313 
high quality and homogenous universal health care is provided to its residents free of charge 314 
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irrespective of socioeconomic and other statuses. This made our cohort a true 315 
representative of the general population avoiding bias due to skewed demographics. 316 
Certain factors that are known to affect pregnancy outcome, such as ethnicity, parity, 317 
maternal age and BMI, socio economic deprivation, smoking status and pre-pregnancy 318 
insulin-dependent diabetes mellitus, have been adjusted for in our analysis. We have made 319 
an effort to look for lesser researched possible associations such as miscarriage and 320 
neonatal/perinatal death. Despite these strengths, our study is not without limitations. The 321 
data for potential confounding factors (existing prognostic factors) was limited to that which 322 
is routinely collected in ou  electronic maternity record as this was a retrospective study. 323 
Similarly, the outcomes are limited to those routinely recorded and thus it was not possible 324 
to look at different thresholds that might confer a more severe outcome e.g. birth weight 325 
<5th or 3rd customised centile or severe pre-eclampsia. However, as our study was designed 326 
to investigate the independent prognostic ability of first trimester factors with adverse 327 
outcome it can be argued that when a factor is prognostic this relationship will be stronger 328 
for higher thresholds for the same outcome. Although the databases used were not 329 
designed for this particular study they are populated by qualified health professionals and 330 
data was obtained from multiple sources to allow cross-referencing and checking of 331 
outcomes. The biochemistry data is part of the National Screening Programme and thus 332 
subject to the relevant quality assurance (UK National external quality assurance scheme 333 
(UKNEQAS), Edinburgh Royal Infirmary, UK and Downs syndrome screening quality 334 
assurance and support service (DQASS), University of Plymouth UK). Our sample was 335 
determined by the number of patients available with an electronic record and outcome data 336 
and thus not determined by a sample size calculation. Most confidence intervals were quite 337 
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narrow, but we recognise that non-significant findings do not necessarily mean that no 338 
prognostic association exists, and may simply reflect a low power to detect genuine 339 
associations. Nevertheless, many confidence intervals were relatively narrow and the 340 
prognostic associations identified were often strongly significant 26. 341 
The clinical utilisation of CRL as an individual prognostic factor (i.e. outside of a model using 342 
it as a continuous factor) is less clear as standard care in the UK is for a single first trimester 343 
ultrasound to incorporate dating (using CRL) and NT for aneuploidy risk. Previous studies 344 
have assessed the prognostic value of difference in expected to observed CRL based on the 345 
last menstrual period10, observed versus expected change in CRL in the first trimester27 and 346 
CRL as a continuous factor in multivariable analysis28. The use of CRL to date a pregnancy 347 
assumes that there is no growth variation within the first trimester nor association with 348 
factors such as fetal sex, maternal age or ethnicity29. A study from the Netherlands 349 
demonstrated that CRL in the first trimester was associated with an increased risk of 350 
adverse birth outcomes and postnatal growth acceleration28. As standard care in the UK is 351 
only to offer one first trimester ultrasound, thus it is not possible to assess CRL change and 352 
the use of the CRL to date the pregnancy does not allow the assessment of observed to 353 
expected CRL. We thus wished to assess whether CRL, measured between the 11+2-14+1 354 
week window, assessed as a continuous variable had a relationship with adverse pregnancy 355 
outcome i.e. in particular assessing extremes of the continuum.  356 
 357 
Interpretation 358 
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The aim was to provide more evidence toward establishing if the prognostic factors of 359 
interest can be used to further inform the management of potential adverse outcomes, for 360 
example by increased surveillance for pregnant women at greater risk. The results showed 361 
evidence of associations between the potential prognostic factors and several outcomes, 362 
and the associations remained largely the same when the factors were considered in 363 
combination. Future work is now important to establish whether the findings from all 364 
prognostic factor studies are consistent by synthesising the evidence. 365 
The evidence from this study supports the need for women with pregnancies with a low 366 
PAPP-A  and increased NT being under Consultant led care and the recommendation within 367 
the RCOG guidelines7 for increased surveillance for SGA in pregnancies with a low PAPP-A 368 
and supports this being extended to pregnancies in the first trimester with an increased NT. 369 
At present until a model is developed that can incorporate these factors as continuous 370 
variables it would be appropriate to use accepted thresholds of <5th centile for PAPP-A and 371 
>99th centile for NT. Due to the association with low PAPP-A and PTB and PE these 372 
pregnancies should be assessed comprehensively for other risk factors for PTB and 373 
consideration given to the commencement of aspirin prior to 16 weeks. Independent 374 
prognostic factors have a broad array of potential uses in both clinical practice and health 375 
research12. For instance, they help to define disease at diagnosis; they may be modifiable in 376 
order for interventions to improve outcomes; they aid the design and analysis of trials; they 377 
are confounders to consider in observational studies and unbalanced trials; and they are the 378 
building blocks of prognostic models 12. Prognostic factor research is therefore important to 379 
discover and evaluate such factors. 380 
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We emphasise that our multivariable models were fitted to examine if there is evidence of 381 
an independent association between the potential prognostic factors of interest and the 382 
maternal and fetal outcomes after adjustment for known prognostic factors. Our objective 383 
was to assess the prognostic factors themselves and not on an overall prognostic model for 384 
individual risk prediction. This is especially important since there was no external data to 385 
validate such a model 13. Future work could use new datasets to develop individual risk 386 
prediction models in order to tailor treatment choices to the individual and to look at 387 
different thresholds for the outcomes e.g. severe PET. Such models should build on the 388 
findings of this study, in te ms of the prognostic factors that were identified as important. 389 
Conclusion 390 
When three first trimester potential prognostic factors are considered in combination there 391 
remains strong evidence of associations between: a) PAPP-A, NT, CRL and SGA, b) PAPP-A 392 
only with PTB, c) PAPP-A and CRL for PE, d) NT and miscarriage. Further work is required to 393 
assess the predictive ability of these factors in prediction models for adverse pregnancy 394 
outcome. 395 
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Legend of tables and figures 480 
Table 1: Mother and fetus demographics and clinical features at the test 481 
Table 2: Number of events for each outcome in singleton pregnancies (N=12,592) and 482 
association with PAPP-A, nuchal translucency and crown rump length (unadjusted logistic 483 
regression) 484 
Table 3: Adjusted odds ratio estimates for the association between each adverse outcome 485 
and PAPP-A, nuchal translucency and crown rump length (adjusted logistic regression) 486 
 487 
Legend of Supporting Information 488 
Table S1: PAPP-A: Results from adjusted logistic regression for SGA (N=12300, M=35 489 
imputed datasets). 490 
Table S2: PAPP-A: Results from adjusted logistic regression for preterm birth (<37 weeks 491 
gestation) (N=12,454, M=35 imputed datasets). 492 
Table S3: PAPP-A: Results from adjusted logistic regression for pre-eclampsia (N=12,322, 493 
M=35 imputed datasets). 494 
Table S4: PAPP-A: Results from adjusted logistic regression for miscarriage (<24 weeks 495 
gestation) (N=10404, M=35 imputed datasets). 496 
Table S5: PAPP-A: Results from adjusted logistic regression for stillbirth (>24 weeks 497 
gestation) (N=9753, M=35 imputed datasets) 498 
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Table S6: PAPP-A: Results from adjusted logistic regression for perinatal death (death 499 
between 24 weeks gestation and 7 days after birth) (N=10898, M=35 imputed datasets). 500 
Table S7: PAPP-A: Results from adjusted logistic regression for neonatal death (death 501 
between birth and 28 days after birth) (N=10876, M=35 imputed datasets). 502 
Table S8: Nuchal translucency: Results from adjusted logistic regression for SGA (N=12299, 503 
M=35 imputed datasets). 504 
Table S9: Nuchal translucency: Results from adjusted logistic regression for preterm birth 505 
(N=12453, M=35 imputed datasets). 506 
Table S10: Nuchal translucency: Results from adjusted logistic regression for pre-eclampsia 507 
(N=12321, M=35 imputed datasets). 508 
Table S11: Nuchal translucency: Results from adjusted logistic regression for miscarriage 509 
(N=10404, M=35 imputed datasets) 510 
Table S12: Nuchal translucency: Results from adjusted logistic regression for stillbirth 511 
(N=9753, M=35 imputed datasets). 512 
Table S13: Nuchal translucency: Results from adjusted logistic regression for perinatal death 513 
(N=10898, M=35 imputed datasets). 514 
Table S14: Nuchal translucency: Results from adjusted logistic regression for neonatal death 515 
(N=10876, M=35 imputed datasets). 516 
Table S15: Crown rump length: Results from adjusted logistic regression for SGA (N=12299, 517 
M=35 imputed datasets). 518 
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Table S16: Crown rump length: Results from adjusted logistic regression for preterm birth 519 
(N=12453, M=35 imputed datasets). 520 
Table S17: Crown rump length: Results from adjusted logistic regression for pre-eclampsia 521 
(N=12321, M=35 imputed datasets). 522 
Table S18: Crown rump length: Results from adjusted logistic regression for miscarriage 523 
(N=10404, M=35 imputed datasets). 524 
Table S19: Crown rump length: Results from adjusted logistic regression for stillbirth 525 
(N=9753, M=35 imputed datasets). 526 
Table S20: Crown rump length: Results from adjusted logistic regression for perinatal death 527 
(N=10898, M=35 imputed datasets). 528 
Table S21: Crown rump length: Results from adjusted logistic regression for neonatal death 529 
(N=10876, M=35 imputed datasets). 530 
Table S22: PAPP-A, NT and CRL: Results from adjusted logistic regression for SGA (N=12299, 531 
M=35 imputed datasets). 532 
Table S23: PAPP-A, NT and CRL: Results from adjusted logistic regression for preterm birth 533 
(N=12453, M=35 imputed datasets). 534 
Table S24: PAPP-A, NT and CRL: Results from adjusted logistic regression for pre-eclampsia 535 
(N=12321, M=35 imputed datasets). 536 
Table S25: PAPP-A, NT and CRL: Results from adjusted logistic regression for miscarriage 537 
(N=10404, M=35 imputed datasets). 538 
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Table S26: PAPP-A, NT and CRL: Results from adjusted logistic regression for stillbirth 539 
(N=9753, M=35 imputed datasets). 540 
Table S27: PAPP-A, NT and CRL: Results from adjusted logistic regression for perinatal death 541 
(N=10898, M=35 imputed datasets). 542 
Table S28: PAPP-A, NT and CRL: Results from adjusted logistic regression for neonatal death 543 
(N=10876, M=35 imputed datasets). 544 
Table S29: PAPP-A, NT and CRL: Results from adjusted logistic regression for SGA assessing 545 
functional form of PAPP-A, NT and CRL (N=12299, M=35 imputed datasets). 546 
Table S30: PAPP-A, NT and CRL: Results from adjusted logistic regression for preterm birth 547 
assessing functional form of PAPP-A, NT and CRL (N=12453, M=35 imputed datasets). 548 
Table S31: PAPP-A, NT and CRL: Results from adjusted logistic regression for pre-eclampsia 549 
assessing functional form of PAPP-A, NT and CRL (N=12321, M=35 imputed datasets). 550 
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Table 1: Mother and fetus demographics and clinical features at the test. 551 
 Summary (N=12,592) 
Mother’s age (years) 30.6 (5.6) 
Gestational age at test (days) 88.2 (4.3) 
Parity (number) 1 [0,1] 
BMI 25.1 [22.4, 28.8] 
Deprivation score*, n (%) 
≤8.49 455 (3.6) 
8.5 – 13.79 846 (6.7) 
13.8 – 21.35 2629 (20.9) 
21.36 – 34.17 2992 (23.8) 
≥34.18 5495 (43.6) 
Missing 175 (1.4) 
Ethnicity, n (%) 
African-Caribbean 944 (7.5) 
South-Asian 2502 (19.9) 
Oriental 358 (2.8) 
Other mixed 898 (7.1) 
White 7879 (62.6) 
Not stated 11 (0.1) 
Assisted conception, n (%) 250 (2.0) 
Smoking status, n (%) 
Smoker 1569 (12.4) 
Non-smoker 10611 (84.3) 
Stopped during 
pregnancy 
412 (3.3) 
Pre-pregnancy insulin-dependent  
Diabetes mellitus, n (%) 
36 (0.3) 
Gender of baby, n (%) 
Male 6118 (48.6) 
Female 6435 (51.1) 
Missing 39 (0.3) 
Mean (standard deviation) or median [interquartile range] for continuous variables and n (%) for 552 
categorical variables; * Deprivation score calculated using the National Perinatal Epidemiology Unit 553 
Index of Multiple Deprivation (NPEU IMD) calculator. BMI: body mass index 554 
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Table 2: Number of events for each outcome in singleton pregnancies (N=12,592) and unadjusted association with PAPP-A, nuchal translucency and 555 
crown rump length and each outcome (univariable logistic regression). 556 
Outcome 
Number of events 
(%) 
PAPP-A (U/L) Nuchal translucency (mm) Crown rump length (mm) 
Odds ratio (95% CI), p-value Odds ratio (95% CI), p-value Odds ratio (95% CI), p-value 
SGA (<10th customised 
centile) 
1824 (14.5) 0.87 (0.85 to 0.90), <0.0001 0.81 (0.72 to 0.91), <0.0001 0.99 (0.99 to 1.00), 0.065 
Pre-term birth (<37 
weeks) 
852 (6.77) 0.93 (0.90 to 0.97), <0.0001 1.15 (1.00 to 1.32), 0.053 1.00 (0.99 to 1.01), 0.730 
Pre-eclampsia 352 (2.80) 0.92 (0.86 to 0.97), 0.004 0.90 (0.70 to 1.14), 0.378 1.01 (1.00 to 1.02), 0.123 
Miscarriage (death prior 
to birth <24 weeks 
gestation) 
73 (0.58) 0.97 (0.86 to 1.09), 0.598 1.94 (1.54 to 2.45), <0.0001 1.02 (0.99 to 1.05), 0.147 
Stillbirth (death prior to 
birth >24 weeks 
gestation) 
37 (0.29) 0.81 (0.66 to 1.00), 0.052 0.77 (0.35 to 1.68), 0.503 0.97 (0.93 to 1.01), 0.150 
Perinatal death* (Death 
between 24 weeks 
gestation and 7 days after 
birth) 
73 (0.58) 0.93 (0.82 to 1.05), 0.245 0.70 (0.39 to 1.23), 0.213 0.98 (0.95 to 1.01), 0.160 
Neonatal death$ (Death 
between birth and 28 
days) 
38 (0.31) 1.03 (0.89 to 1.20), 0.686 0.57 (0.25 to 1.29), 0.176 0.98 (0.95 to 1.02), 0.432 
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* Perinatal death includes stillbirths; 
$
 neonatal death includes babies that die between birth and 7 days after birth that are captured within the perinatal 557 
death category. SGA small for gestational age (birth weight<10th customised centile. Odds ratios indicate the effect of 1 –unit increase in the factor on the 558 
odds of the outcome.559 
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Table 3: Adjusted odds ratio estimates for the association between each adverse outcome and PAPP-A, nuchal translucency and crown rump length. 560 
Outcome PAPP-A (U/L) OR (95% CI), p-value NT (mm) OR (95% CI), p-value CRL (mm) OR (95% CI), p-value 
SGA (<10
th
 customised centile) 0.88 (0.85 to 0.91), <0.0001 0.79 (0.70 to 0.89), <0.0001 0.99 (0.99 to 1.00), 0.057 
Preterm birth (<37 weeks) 0.92 (0.88 to 0.97), <0.0001 1.09 (0.93 to 1.27), 0.313 1.00 (0.99 to 1.01), 0.624 
Pre-eclampsia toxaemia 0.91 (0.85 to 0.97), 0.003 0.87 (0.67 to 1.12), 0.287 1.01 (0.99 to 1.02), 0.325 
Miscarriage (death <24 weeks gestation) 1.01 (0.84 to 1.21), 0.929 1.75 (1.12 to 2.72), 0.013 1.03 (0.99 to 1.07), 0.129 
Stillbirth (death >24 weeks gestation) 0.71 (0.52 to 0.98), 0.038 0.69 (0.25 to 1.93), 0.485 0.94 (0.89 to 0.99), 0.027 
Perinatal death (death between 24 weeks 
gestation and 7 days after birth) 
0.88 (0.73 to 1.06), 0.173 0.89 (0.43 to 1.83), 0.746 0.97 (0.93 to 1.01), 0.110 
Neonatal death (death between birth and 
28 days) 
1.04 (0.85 to 1.29), 0.687 1.07 (0.39 to 2.93), 0.896 1.00 (0.95 to 1.05), 0.919 
OR odds ratio; CI confidence interval; NT nuchal translucency; CRL crown rump length; SGA small for gestational age; all odds ratio estimates for PAPP-A, NT 561 
and CRL from separate multivariable models, adjusted for maternal age, BMI, parity, ethnicity, deprivation score, smoking status, IVF, and gestational 562 
diabetes. 563 
 564 
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